DelveInsight’s, “Immune Thrombocytopenia Pipeline Insight, 2023,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the Immune Thrombocytopenia pipeline landscape. It covers the pipeline drug profiles, including Immune Thrombocytopenia clinical trials and nonclinical stage products. It also covers the Immune Thrombocytopenia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Immune Thrombocytopenia pipeline report, a detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Immune Thrombocytopenia NDA approvals (if any), and product development activities comprising the technology, Immune thrombocytopenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Immune Thrombocytopenia Pipeline Report

 

• DelveInsight’s Immune Thrombocytopenia Pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Immune Thrombocytopenia treatment.

 

• The leading Immune Thrombocytopenia Companies includes UCB, arGEN-X, HanAll Biopharma/Immunovant, Momenta Pharmaceuticals, Principia Biopharma, Hutchison MediPharma, Cour Pharmaceutical Development, and others.

 

• Promising Immune Thrombocytopenia Pipeline Therapies includes ARGX-113, Romiplostim, LIV-GAMMA SN Inj.10%, Rozanolixizumab, LIV-GAMMA SN Inj., QL0911, Romiplostim, BT595, Efgartigimod, and others.

 

• The Immune Thrombocytopenia companies and academics are working to assess challenges and seek opportunities that could influence Immune thrombocytopenia R&D. The Immune Thrombocytopenia pipeline therapies under development are focused on novel approaches to treat/improve Immune thrombocytopenia.

 

To explore more information on the latest breakthroughs in the Immune Thrombocytopenia Pipeline treatment landscape of the report, click here @ Immune Thrombocytopenia Pipeline Outlook

 

Immune Thrombocytopenia Overview

Immune thrombocytopenia (ITP), formerly known as Idiopathic thrombocytopenic purpura is an autoimmune bleeding disorder. The disease is characterized by abnormally low levels of blood cells called platelets. ITP manifests as a bleeding tendency, easy bruising (purpura), or extravasation of blood from capillaries into skin and mucous membranes (petechiae). The diagnosis of ITP is made by excluding other causes of thrombocytopenia along with blood tests. Treatment for ITP is based on goals to prevent bleeding and stabilize as well as improvement in platelet count. Corticosteroid drugs like prednisone, dexamethasone, and methylprednisolone is usually the mainstay of first line therapy. In 2008, the FDA approved Nplate and Promacta to treat both children and adults with ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

 

Latest Developmental Activities in the Immune Thrombocytopenia Treatment Landscape

 

• Rozanolixizumab has received orphan drug designation by the USFDA on 30 April 2018 and by the European Commission on 11 January 2019 for its use in the ITP market.

 

• In November 2020, Rilzabrutinib received Fast Track Designation (FTD) by USFDA and is currently under a Phase 3 study for ITP. Rilzabrutinib received an orphan drug designation from the FDA for the treatment of ITP in October 2018.

 

 

For further information, refer to the detailed Immune Thrombocytopenia Unmet Needs, Immune Thrombocytopenia Market Drivers, and Immune Thrombocytopenia Market Barriers, click here for Immune Thrombocytopenia Ongoing Clinical Trial Analysis

 

Immune Thrombocytopenia Emerging Drugs Profile

 

Rozanolixizumab (UCB7665): UCB

Rozanolixizumab humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P). By blocking IgG recycling, this subcutaneously infused monoclonal antibody aims to improve the course of immunoglobulin G (IgG)-mediated autoimmune diseases by reducing pathogenic autoantibody levels. Rozanolixizumab, an investigational monoclonal antibody, was granted orphan drug designation for the treatment of ITP by the US Food and Drug Administration on 30 April 2018 and by the European Commission on 11 January 2019. The drug is in Phase III clinical studies for the treatment of idiopathic thrombocytopenic purpura, myasthenia gravis and in Phase II clinical studies for chronic inflammatory demyelinating polyradiculoneuropathy and encephalitis.

 

Efgartigimod: arGEN-X

Efgartigimod is designed as a first-in-class investigational antibody fragment to target the neonatal Fc receptor (FcRn). Efgartigimod is being evaluated for the treatment of patients with severe autoimmune diseases with confirmed presence of pathogenic immunoglobulin G, IgG autoantibodies, where a severe unmet medical need exists. The drug is in registration phase for myasthenia gravis and in Phase III clinical studies for Primary Immune Thrombocytopenia (ITP), chronic inflammatory demyelinating polyradiculoneuropathy, and Pemphigus vulgaris.

 

Immune Thrombocytopenia Pipeline Therapeutics Assessment

There are approx. 30+ key companies which are developing the therapies for Immune thrombocytopenia. The companies which have their Immune thrombocytopenia drug candidates in the most advanced stage, i.e. Phase III include, UCB.

 

Request a sample and discover the recent advances in Immune Thrombocytopenia Ongoing Clinical Trial Analysis and Medications, click here @ Immune Thrombocytopenia Treatment Landscape

 

Scope of the Immune Thrombocytopenia Pipeline Report

 

• Coverage- Global

 

• Immune Thrombocytopenia Companies- UCB, arGEN-X, HanAll Biopharma/Immunovant, Momenta Pharmaceuticals, Principia Biopharma, Hutchison MediPharma, Cour Pharmaceutical Development, and others

 

• Immune Thrombocytopenia Pipeline Therapies- ARGX-113, Romiplostim, LIV-GAMMA SN Inj.10%, Rozanolixizumab, LIV-GAMMA SN Inj., QL0911, Romiplostim, BT595, Efgartigimod, and others.

 

• Immune Thrombocytopenia Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Immune Thrombocytopenia Market Drivers and Immune Thrombocytopenia Market Barriers, click here @ Immune Thrombocytopenia Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Immune thrombocytopenia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Immune thrombocytopenia – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Rozanolixizumab (UCB7665): UCB
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical/Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Immune thrombocytopenia Key Companies
21. Immune thrombocytopenia Key Products
22. Immune thrombocytopenia- Unmet Needs
23. Immune thrombocytopenia- Market Drivers and Barriers
24. Immune thrombocytopenia- Future Perspectives and Conclusion
25. Immune thrombocytopenia Analyst Views
26. Appendix

 

Got Queries? Find out the related information on Immune Thrombocytopenia Mergers and acquisitions, Immune Thrombocytopenia Licensing Activities @ Immune Thrombocytopenia Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/